Rivaroxaban, in combination with low-dose aspirin, is associated with a reduction in proinflammatory and prothrombotic circulating vesicle signatures in patients with cardiovascular disease
Luisa Weiß, Aideen O’Doherty, Wido Uhrig, Paulina B. Szklanna, Molly Hong-Minh, Kieran Wynne, Alfonso Blanco, Jan Zivny, Valéria Lima Passos, Barry Kevane, Séan Murphy, Fionnuala Ní Áinle, Martin O’Donnell, Patricia B. Maguire
Topics & Concepts
RivaroxabanMedicineAspirinDiseaseReduction (mathematics)InflammationInternal medicineCardiologyPharmacologyAtrial fibrillationWarfarinGeometryMathematicsExtracellular vesicles in diseaseNeutrophil, Myeloperoxidase and Oxidative MechanismsProtease and Inhibitor Mechanisms